Royal London Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Royal London Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-76,035	Closed	-$14M	–	680
2021 Q2	$14M	Buy	+76,035	New	+$13.1M	0.06%	271
2021 Q1	–	Sell	-79,126	Closed	-$12.4M	–	748
2020 Q4	$12.4M	Sell	79,126 -1,926	-2%	-$247K	0.06%	250
2020 Q3	$9.12M	Hold	81,052	–	–	0.06%	277
2020 Q2	$9.02M	Sell	81,052 -4,801	-6%	-$510K	0.06%	268
2020 Q1	$7.49M	Sell	85,853 -470	-0.5%	-$46.1K	0.06%	281
2019 Q4	$9.27M	Hold	86,323	–	–	0.06%	279
2019 Q3	$8.45M	Buy	+86,323	New	+$9.73M	0.06%	298
2019 Q2	–	Sell	-90,158	Closed	-$12.2M	–	654
2019 Q1	$12.2M	Sell	90,158 -1,237	-1%	-$154K	0.1%	222
2018 Q4	$8.88M	Buy	91,395 +6,619	+8%	+$782K	0.08%	258
2018 Q3	$11.8M	Sell	84,776 -5,863	-6%	-$735K	0.12%	179
2018 Q2	$11.3M	Buy	+90,639	New	+$10.6M	0.11%	195
2016 Q2	$8.8M	Sell	75,344 -7,562,666	-99%	-$1.07B	0.14%	153
2016 Q1	$55K	Buy	7,638,010 +7,557,377	+9,373%	+$1.11B	0.08%	284
2015 Q4	$15.4M	Buy	80,633 +537	+0.7%	+$93.8K	0.24%	100
2015 Q3	$12.5M	Buy	+80,096	New	+$14.6M	0.2%	117
2014 Q3	–	Sell	-46,078	Closed	-$7.31M	–	577
2014 Q2	$7.31M	Sell	46,078 -200	-0.4%	-$31.6K	0.17%	141
2014 Q1	$7.46M	Buy	46,278 +595	+1%	+$94.6K	0.17%	136
2013 Q4	$6.18M	Buy	45,683 +575	+1%	+$69K	0.16%	151
2013 Q3	$5.26M	Buy	45,108 +668	+2%	+$73.3K	0.14%	171
2013 Q2	$4.17M	Buy	+44,440	New	+$4.28M	0.12%	193

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Royal London Asset Management's ALXN Position: Q3 2021 in Review

Royal London Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 76,035 shares — an estimated $14M sold.

Royal London Asset Management first reported a position in ALXN in Q2 2013 and held it in 20 quarters. The position peaked at $15.4M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Royal London Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Royal London Asset Management sold 76,035 Alexion Pharmaceuticals shares in Q3 2021, an estimated $14M.
Royal London Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 20 quarters.
Royal London Asset Management's Alexion Pharmaceuticals position peaked at $15.4M in Q4 2015.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Royal London Asset Management's 13F filing for Q3 2021, filed 2 Nov 2021.